PRESS RELEASE

Q1 2024 — Press release

Q1 2024PDF · 12 pages279 KB
News Release
____________________________________________________________________________
Merck Announces First-Quarter 2024 Financial Results
- 	Sales Reflect Continued Strong Growth in Oncology and Vaccines
- 	Total Worldwide Sales Were $15.8 Billion, an Increase of 9% From First Quarter 2023;
Excluding the Impact of Foreign Exchange, Growth Was 12%
o 	KEYTRUDA Sales Grew 20% to $6.9 Billion; Excluding the Impact of Foreign
Exchange, Sales Grew 24%
o 	GARDASIL/GARDASIL 9 Sales Grew 14% to $2.2 Billion; Excluding the Impact
of Foreign Exchange, Sales Grew 17%
- 	GAAP EPS Was $1.87; Non-GAAP EPS Was $2.07; GAAP and Non-GAAP EPS Include
a Charge of $0.26 per Share for Acquisition of Harpoon
- 	Received FDA Approval of WINREVAIR, a First-in-Class Treatment for Adults With
Pulmonary Arterial Hypertension (WHO Group 1)
- 	Made Meaningful Regulatory and Clinical Progress Across Other Therapeutic Areas,
Including Oncology, Vaccines and Infectious Diseases
- 	Expanded Pipeline and Portfolio Through Business Development, Including Completed
Acquisition of Harpoon and Proposed Acquisition of Elanco’s Aqua Business
- 	Full-Year 2024 Financial Outlook
o 	Raises and Narrows Expected Worldwide Sales Range To Be Between $63.1
Billion and $64.3 Billion
o 	Raises and Narrows Expected Non-GAAP EPS Range To Be Between $8.53
and $8.65
RAHWAY, N.J., April 25, 2024 – Merck (NYSE: MRK), known as MSD outside the United States
and Canada, today announced financial results for the first quarter of 2024.
“Merck has begun 2024 with continuing momentum in our business. We are harnessing
the power of innovation to advance our deep pipeline and are maximizing the impact of our
broad commercial portfolio for the benefit of patients,” said Robert M. Davis, chairman and chief
executive officer, Merck. “We drove strong growth across key therapeutic areas, executed
strategic business development, and in the U.S., we are now launching WINREVAIR, a
significant new product in the cardiometabolic space for adults with pulmonary arterial
hypertension, a progressive and debilitating disease. We have important opportunities ahead of
us across all areas of our business, and we are highly focused on realizing them.”

-- 1 of 12 --

- 2 -
Financial Summary
$ in millions, except EPS amounts
First Quarter
2024 	2023 	Change
Change Ex-
Exchange
Sales 	$15,775 	$14,487 	9% 	12%
GAAP net income1 	4,762 	2,821 	69% 	76%
Non-GAAP net income that excludes certain items 1,2* 	5,279 	3,564 	48% 	54%
GAAP EPS 	1.87 	1.11 	68% 	76%
Non-GAAP EPS that excludes certain items 2* 	2.07 	1.40 	48% 	54%
*Refer to table on page 6.
Generally Accepted Accounting Principles (GAAP) earnings per share (EPS) assuming
dilution was $1.87 for the first quarter of 2024. Non-GAAP EPS was $2.07 for the first quarter of
2024. GAAP and non-GAAP EPS in the first quarter of 2024 include a charge of $0.26 per share
for the acquisition of Harpoon Therapeutics, Inc. (Harpoon). GAAP and non-GAAP EPS in the
first quarter of 2023 include charges of $0.52 per share related to the acquisition of Imago
BioSciences, Inc. (Imago) and a collaboration and licensing agreement with Kelun-Biotech.
Non-GAAP EPS excludes acquisition- and divestiture-related costs, costs related to
restructuring programs, as well as income and losses from investments in equity securities.
Non-GAAP EPS for the first quarter of 2023 also excludes a charge related to settlements with
certain plaintiffs in the Zetia antitrust litigation.
1 Net income attributable to Merck & Co., Inc.
2 Merck is providing certain 2024 and 2023 non-GAAP information that excludes certain items because of the nature of these items
and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this
information enhances investors’ understanding of the company’s results because management uses non-GAAP results to assess
performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the
performance of the company along with other metrics. In addition, annual employee compensation, including senior management’s
compensation, is derived in part using a non-GAAP pretax income metric. This information should be considered in addition to, but
not as a substitute for or superior to, information prepared in accordance with GAAP. For a description of the non-GAAP
adjustments, see Table 2a attached to this release.

-- 2 of 12 --

- 3 -
First-Quarter Sales Performance
The following table reflects sales of the company’s top products and significant
performance drivers.
First Quarter
$ in millions 	2024 	2023 	Change
Change
Ex-
Exchange 	Commentary
Total Sales 	$15,775 	$14,487 	9% 	12%
Approximately 2% of the negative impact of
foreign exchange was due to devaluation of
Argentine peso, which was largely offset by
inflation-related price increases, consistent
with practice in that market.
Pharmaceutical 	14,006 	12,721 	10% 	13%
Increase driven by growth in oncology and
vaccines, partially offset by a decline in
diabetes.
KEYTRUDA 	6,947 	5,795 	20% 	24%
Growth driven by increased global uptake in
earlier-stage indications, including triple-
negative breast cancer and renal cell
carcinoma, as well as non-small cell lung
cancer (NSCLC) in the U.S., and continued
strong global demand from metastatic
indications. Substantially all of the 4% negative
impact of foreign exchange was due to
devaluation of Argentine peso, which was
largely offset by inflation-related price
increases.
GARDASIL/
GARDASIL 9 	2,249 	1,972 	14% 	17%
Growth due to strong demand, particularly in
China, which also benefited from timing of
shipments, as well as public-sector buying
patterns in the U.S., and higher pricing.
JANUVIA/JANUMET 	670 	880 	-24% 	-21%
Decline primarily due to lower pricing and
demand in the U.S., as well as ongoing
generic competition in many international
markets, particularly in Europe, Canada and
the Asia Pacific region.
PROQUAD, M-M-R II
and VARIVAX 	570 	528 	8% 	8%
Growth largely from higher pricing in the U.S.,
as well as higher sales in Latin America, due in
part to timing of government tenders.
BRIDION 	440 	487 	-10% 	-8%
Decline primarily due to generic competition in
certain ex-U.S. markets, particularly in Europe,
partially offset by higher demand in the U.S.
LAGEVRIO 	350 	392 	-11% 	-5%
Decline due to lower demand in certain
markets in the Asia Pacific region, partially
offset by higher demand in Japan and the U.S.
Lynparza* 	292 	275 	6% 	7%
Growth driven primarily by higher demand in
certain international markets, particularly in
Latin America.
Lenvima* 	255 	232 	10% 	10%
Growth primarily from higher demand in the
U.S.
VAXNEUVANCE 	219 	106 	106% 	106%
Growth largely driven by continued uptake for
pediatric indication in the U.S. and launches in
Europe. Sales growth in the U.S. also
benefited from public-sector buying patterns.
ROTATEQ 	216 	297 	-27% 	-27%
Decline primarily due to timing of shipments in
China and public-sector buying patterns in the
U.S.

-- 3 of 12 --

- 4 -
Animal Health 	1,511 	1,491 	1% 	4%
Growth primarily driven by higher pricing in
both Livestock and Companion Animal product
portfolios, partially offset by lower volumes.
Approximately 2% of the negative impact of
foreign exchange was due to devaluation of
Argentine peso, which was largely offset by
inflation-related price increases.
Livestock 	850 	849 	0% 	4%
Sales were flat reflecting higher pricing across
product portfolio, as well as higher demand for
swine and poultry products, partially offset by
lower demand for ruminant products.
Companion Animal 	661 	642 	3% 	4%
Growth due to higher pricing across product
portfolio. Sales of BRAVECTO were $332
million and $314 million in current and prior-
year quarters, respectively, which represented
growth of 6%, or 7% excluding impact of
foreign exchange.
Other Revenues** 	258 	275 	-6% 	11%
Decline due to impact of revenue hedging
activities.
*Alliance revenue for this product represents Merck’s share of profits, which are product sales net of cost of sales and commercialization
costs.
**Other revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues,
including revenue hedging activities.
First-Quarter Expense, EPS and Related Information
The table below presents selected expense information.
$ in millions 	GAAP
Acquisition-
and
Divestiture-
Related
Costs3
Restructuring
Costs
(Income)
Loss From
Investments
in Equity
Securities
Certain
Other
Items
Non-
GAAP2
First Quarter 2024
Cost of sales 	$3,540 	$463 	$116 	$- 	$- 	$2,961
Selling, general and
administrative 	2,483 	21 	5 	- 	- 	2,457
Research and development 	3,992 	16 	2 	- 	- 	3,974
Restructuring costs 	123 	- 	123 	- 	- 	-
Other (income) expense,
net 	(33) 	(4) 	- 	(116) 	- 	87
First Quarter 2023
Cost of sales 	$3,926 	$545 	$29 	$- 	$- 	$3,352
Selling, general and
administrative 	2,479 	20 	1 	-
-
2,458
Research and development 	4,276 	10 	- 	- 	- 	4,266
Restructuring costs 	67 	- 	67 	- 	- 	-
Other (income) expense,
net 	89 	15 	- 	(429) 	573 	(70)
3 Includes expenses for the amortization of intangible assets recognized as a result of acquisitions of businesses, intangible asset
impairment charges and expense or income related to changes in the estimated fair value measurement of liabilities for contingent
consideration. Also includes integration, transaction and certain other costs associated with acquisitions and divestitures, as well
as amortization of intangible assets related to collaborations and licensing arrangements.

-- 4 of 12 --

- 5 -
GAAP Expense, EPS and Related Information
Gross margin was 77.6% for the first quarter of 2024 compared with 72.9% for the first
quarter of 2023. The increase was primarily due to the favorable impacts of product mix
(including lower royalty rates related to KEYTRUDA and GARDASIL/GARDASIL 9), foreign
exchange and lower amortization of intangible assets, partially offset by higher restructuring
costs and inventory write-offs.
Selling, general and administrative (SG&A) expenses were $2.5 billion in both the first
quarters of 2024 and 2023, primarily due to higher administrative costs, offset by lower
promotional costs, reflecting the prioritization of spending on key growth products, and the
favorable impact of foreign exchange.
Research and development (R&D) expenses were $4.0 billion in the first quarter of 2024
compared with $4.3 billion in the first quarter of 2023. The decrease was primarily due to lower
charges for business development activity, which included a $656 million charge for the
acquisition of Harpoon in the first quarter of 2024, compared with charges of $1.2 billion for the
acquisition of Imago and $175 million for a license and collaboration agreement with Kelun-
Biotech in the first quarter of 2023. The decline was partially offset by increased compensation
and benefit costs, higher clinical development spending, as well as higher investments in
discovery research and early drug development in the first quarter of 2024.
Other (income) expense, net, was $33 million of income in the first quarter of 2024
compared with $89 million of expense in the first quarter of 2023. The favorability primarily
reflects a $572.5 million charge in 2023 related to settlements with certain plaintiffs in the Zetia
antitrust litigation, largely offset by lower income from investments in equity securities and
higher net interest expense in 2024.
The effective tax rate was 15.9% for the first quarter of 2024 (which includes a 1.6
percentage point unfavorable impact for the acquisition of Harpoon), compared with 22.6% in
the first quarter of 2023 (which includes a 5.5 percentage point unfavorable impact for the
acquisition of Imago).
GAAP EPS was $1.87 for the first quarter of 2024 compared with $1.11 for the first
quarter of 2023.
Non-GAAP Expense, EPS and Related Information
Non-GAAP gross margin was 81.2% for the first quarter of 2024 compared with 76.9%
for the first quarter of 2023. The increase was primarily due to the favorable impacts of product
mix (including lower royalty rates related to KEYTRUDA and GARDASIL/GARDASIL 9) and
foreign exchange, partially offset by higher inventory write-offs.
Non-GAAP SG&A expenses were $2.5 billion for both the first quarters of 2024 and
2023, primarily due to higher administrative costs, offset by lower promotional costs, reflecting

-- 5 of 12 --

- 6 -
the prioritization of spending on key growth products, and the favorable impact of foreign
exchange.
Non-GAAP R&D expenses were $4.0 billion in the first quarter of 2024 compared with
$4.3 billion in the first quarter of 2023. The decrease was primarily due to lower charges for
business development activity, which included a $656 million charge for the acquisition of
Harpoon in the first quarter of 2024, compared with charges of $1.2 billion for the acquisition of
Imago and $175 million for a license and collaboration agreement with Kelun-Biotech in the first
quarter of 2023. The decline was partially offset by increased compensation and benefit costs,
higher clinical development spending, as well as higher investments in discovery research and
early drug development in the first quarter of 2024.
Non-GAAP other (income) expense, net, was $87 million of expense in the first quarter
of 2024 compared with $70 million of income in the first quarter of 2023, primarily due to higher
net interest expense.
The non-GAAP effective tax rate was 16.1% for the first quarter of 2024 (which includes
a 1.5 percentage point unfavorable impact for the acquisition of Harpoon), compared with 20.4%
in the first quarter of 2023 (which includes a 4.3 percentage point unfavorable impact for the
acquisition of Imago).
Non-GAAP EPS was $2.07 for the first quarter of 2024 compared with $1.40 for the first
quarter of 2023.
A reconciliation of GAAP to non-GAAP net income and EPS is provided in the table that
follows.
First Quarter
$ in millions, except EPS amounts 	2024 	2023
EPS
GAAP EPS 	$1.87 	$1.11
Difference 	0.20 	0.29
Non-GAAP EPS that excludes items listed below2 	$2.07 	$1.40
Net Income
GAAP net income1 	$4,762 	$2,821
Difference 	517 	743
Non-GAAP net income that excludes items listed below1,2 	$5,279 	$3,564
Excluded Items:
Acquisition- and divestiture-related costs3 	$496 	$590
Restructuring costs 	246 	97
Income from investments in equity securities 	(116) 	(429)
Charge for Zetia antitrust litigation settlements 	- 	573
Net decrease in income before taxes 	626 	831
Estimated income tax (benefit) expense 	(109) 	(88)
Decrease in net income 	$517 	$743

-- 6 of 12 --

- 7 -
Pipeline and Portfolio Highlights
Merck continued to achieve key regulatory and clinical milestones across therapeutic
areas in the first quarter.
In cardiometabolic disease, Merck received approval from the U.S. Food and Drug
Administration (FDA) for WINREVAIR (sotatercept-csrk) for the treatment of adults with
pulmonary arterial hypertension (PAH, World Health Organization [WHO] Group 1) to increase
exercise capacity, improve WHO functional class, and reduce the risk of clinical worsening
events. WINREVAIR is a breakthrough biologic and the first FDA-approved activin signaling
inhibitor therapy for PAH, a rare, progressive disease. WINREVAIR is currently under review in
the European Union and is being evaluated in ongoing Phase 3 trials in additional PAH patient
populations.
In oncology, KEYTRUDA continued to demonstrate its role as a foundational therapy for
certain types of cancers, receiving the first approval in Europe for an anti-PD-1/L1 therapy as
part of a treatment regimen for adult patients with resectable NSCLC at high risk of recurrence.
In addition, the FDA granted Priority Review to a new supplemental Biologics License
Application (sBLA) that would establish KEYTRUDA as the first immunotherapy indicated for the
frontline treatment of advanced endometrial cancer regardless of DNA mismatch repair status.
Merck also made meaningful progress in its clinical development programs, including initiating a
Phase 3 trial for MK-1084, its investigational oral selective KRAS G12C inhibitor, in combination
with KEYTRUDA for the first-line treatment of certain patients with metastatic NSCLC. And, in
collaboration with Daiichi Sankyo, the company initiated the REJOICE-OVARIAN01 Phase 2/3
trial evaluating the efficacy and safety of investigational raludotatug deruxtecan (R-DXd) in
patients with platinum-resistant ovarian cancer.
In vaccines, Merck shared positive data from multiple Phase 3 studies evaluating V116,
the company’s investigational, 21-valent pneumococcal conjugate vaccine designed for adults.
If approved, V116 would be the first pneumococcal conjugate vaccine designed to address the
serotypes responsible for approximately 83% of invasive pneumococcal disease in adults 65
and older. Merck also announced plans to initiate clinical development of a new investigational,
multi-valent HPV vaccine designed to provide broader protection against certain cancers and
diseases caused by additional HPV types, as well as plans to conduct clinical trials in both
females and males (16-26 years old) to evaluate the efficacy and safety of a single-dose
regimen of GARDASIL 9.
In infectious diseases, Merck presented new data from its HIV development programs at
the 31st Conference on Retroviruses and Opportunistic Infections in March, demonstrating
significant momentum within the HIV pipeline. These data included the Phase 2 study
evaluating a once-weekly oral combination regimen of islatravir, the company’s investigational
nucleoside reverse transcriptase translocation inhibitor (NRTTI), and Gilead Sciences, Inc.’s
lenacapavir, a first-in-class capsid inhibitor, for the treatment of adults living with HIV. And, for
the first time, Merck presented data for MK-8527, the company's novel NRTTI that is being

-- 7 of 12 --

- 8 -
developed as an oral once-monthly agent for HIV-1 pre-exposure prophylaxis (PrEP), which
recently entered Phase 2 development.
Merck has the following three Prescription Drug User Fee Act (PDUFA), or target action,
dates set by the FDA in the second quarter of 2024: V116 (June 17), KEYTRUDA plus
chemotherapy as treatment for primary advanced or recurrent endometrial carcinoma (June 21)
and, in collaboration with Daiichi Sankyo, patritumab deruxtecan (HER3-DXd) for the treatment
of certain patients with previously treated locally advanced or metastatic EGFR-mutated NSCLC
(June 26).
Merck continued to expand and complement its pipeline and product portfolio through
business development. Merck completed the acquisition of Harpoon, expanding its oncology
pipeline with novel T-cell engagers, including MK-6070, an investigational delta-like ligand 3
targeting T-cell engager. The company also entered into a definitive agreement to acquire the
aqua business of Elanco Animal Health Incorporated (Elanco), which will broaden its aqua
portfolio with new products.
Notable recent news releases on Merck’s pipeline and portfolio are provided in the table
that follows.
Cardiometabolic FDA Approved Merck’s WINREVAIR, a First-in-Class Treatment for Adults
With PAH, Based on Results From Phase 3 STELLAR Trial
(Read
Announcement)
Oncology
European Commission Approved Merck’s KEYTRUDA Plus Chemotherapy
as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant
Treatment, for Resectable NSCLC at High Risk of Recurrence in Adults,
Based on Results From Phase 3 KEYNOTE-671 Trial
(Read
Announcement)
FDA Granted Priority Review to Merck’s Application for KEYTRUDA Plus
Chemotherapy as Treatment for Primary Advanced or Recurrent
Endometrial Carcinoma, Based on Results From Phase 3 NRG-GY018
Trial
(Read
Announcement)
KEYTRUDA Plus Chemoradiotherapy (CRT) Significantly Improved
Overall Survival Versus CRT Alone in Patients With Newly Diagnosed
High-Risk Locally Advanced Cervical Cancer, Based on Results From
Phase 3 KEYNOTE-A18 Trial
(Read
Announcement)
Merck and Daiichi Sankyo Initiated REJOICE-Ovarian01 Phase 2/3 Trial of
Raludotatug Deruxtecan in Patients With Platinum-Resistant Ovarian
Cancer
(Read
Announcement)
Merck Initiated Phase 3 Clinical Trial of MK-1084, an Investigational Oral
KRAS G12C Inhibitor, in Combination With KEYTRUDA for First-Line
Treatment of Certain Patients With Metastatic NSCLC
(Read
Announcement)
Vaccines
Merck Announced Positive Data on V116, an Investigational, 21-Valent
Pneumococcal Conjugate Vaccine Specifically Designed for Adults,
Demonstrated Immune Responses in Adults, Based on Results From
Multiple Phase 3 Trials
(Read
Announcement)
Merck Announced Plans to Conduct Clinical Trials of a Novel
Investigational Multi-Valent HPV and Single-Dose Regimen for GARDASIL
9
(Read
Announcement)
Infectious
Diseases
Merck and Gilead Announced Phase 2 Data Showing an Investigational
Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir
Maintained Viral Suppression at Week 24
(Read
Announcement)

-- 8 of 12 --

- 9 -
Upcoming Investor Event
Merck will host an Oncology Investor Event to coincide with the American Society for
Clinical Oncology Annual Meeting on Monday, June 3, 2024, 6 p.m. CT, at which senior
management will provide an update on the company’s oncology strategy and program. The
event will take place in Chicago, Ill., and will be accessible via live audio webcast at this
weblink.
Full-Year 2024 Financial Outlook
The following table summarizes the company’s full-year financial outlook.
Full Year 2024
Updated 	Prior
Sales * 	$63.1 to $64.3 billion 	$62.7 to $64.2 billion
Non-GAAP Gross margin 2 	Approximately 81% 	Approximately 80.5%
Non-GAAP Operating expenses 2** 	$25.2 to $26.1 billion 	$25.1 to $26.1 billion
Non-GAAP Other (income) expense, net 2 	Approximately $250 million expense 	Approximately $200 million expense
Non-GAAP Effective tax rate2 	14.5% to 15.5% 	14.5% to 15.5%
Non-GAAP EPS2*** 	$8.53 to $8.65 	$8.44 to $8.59
Share count (assuming dilution) 	Approximately 2.55 billion 	Approximately 2.54 billion
*The company does not have any non-GAAP adjustments to sales.
**Includes a one-time R&D charge of $656 million related to the Harpoon acquisition. Outlook does not assume any additional significant
potential business development transactions.
***Includes a one-time charge of $0.26 per share related to the Harpoon acquisition.
Merck has not provided a reconciliation of forward-looking non-GAAP gross margin, non-
GAAP operating expenses, non-GAAP other (income) expense, net, non-GAAP effective tax
rate and non-GAAP EPS to the most directly comparable GAAP measures, given it cannot
predict with reasonable certainty the amounts necessary for such a reconciliation, including
intangible asset impairment charges, legal settlements, and gains and losses from investments
in equity securities either owned directly or through ownership interests in investment funds,
without unreasonable effort. These items are inherently difficult to forecast and could have a
significant impact on the company’s future GAAP results.
Merck continues to experience strong global demand for key growth products in
oncology and vaccines. Consequently, Merck is raising and narrowing its full-year outlook
ranges for sales and non-GAAP EPS.
Merck now expects its full-year 2024 sales to be between $63.1 billion and $64.3 billion,
including a negative impact of foreign exchange of approximately 3% at mid-April 2024
exchange rates. Approximately 2% of the negative impact of foreign exchange is due to the
devaluation of the Argentine peso, which the company expects will largely be offset by inflation-
related price increases, consistent with practice in that market.
Merck continues to expect its full-year non-GAAP effective income tax rate to be
between 14.5% and 15.5%.

-- 9 of 12 --

- 10 -
Merck now expects its full-year non-GAAP EPS to be between $8.53 and $8.65,
including a charge of $0.26 per share for the acquisition of Harpoon that closed in the first
quarter of 2024 and a negative impact of foreign exchange of approximately $0.30 per share.
The negative impact of foreign exchange is primarily due to the devaluation of the Argentine
peso, which the company expects will largely be offset by inflation-related price increases,
consistent with practice in that market.
Consistent with past practice, the financial outlook does not assume additional
significant potential business development transactions.
Full-year 2023 non-GAAP EPS of $1.51 was negatively impacted by charges of $6.21
per share related to certain acquisitions and collaboration agreements.
Non-GAAP EPS excludes acquisition- and divestiture-related costs, costs related to
restructuring programs, income and losses from investments in equity securities, and a
previously disclosed charge related to settlements with certain plaintiffs in the Zetia antitrust
litigation.
Earnings Conference Call
Investors, journalists and the general public may access a live audio webcast of the
earnings conference call on Thursday, April 25, at 9 a.m. ET via this weblink. A replay of the
webcast, along with the sales and earnings news release, supplemental financial disclosures,
and slides highlighting the results, will be available at www.merck.com.
All participants may join the call by dialing (888) 847-9708 (U.S. and Canada Toll-Free)
or (630) 395-0358 and using the access code 4164932.
About Merck
At Merck, known as MSD outside of the United States and Canada, we are unified
around our purpose: We use the power of leading-edge science to save and improve lives
around the world. For more than 130 years, we have brought hope to humanity through the
development of important medicines and vaccines. We aspire to be the premier research-
intensive biopharmaceutical company in the world – and today, we are at the forefront of
research to deliver innovative health solutions that advance the prevention and treatment of
diseases in people and animals. We foster a diverse and inclusive global workforce and operate
responsibly every day to enable a safe, sustainable and healthy future for all people and
communities. For more information, visit www.merck.com and connect with us on X (formerly
Twitter), Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA
This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes
“forward-looking statements” within the meaning of the safe harbor provisions of the U.S.
Private Securities Litigation Reform Act of 1995. These statements are based upon the current
beliefs and expectations of the company’s management and are subject to significant risks and

-- 10 of 12 --

- 11 -
uncertainties. There can be no guarantees with respect to pipeline candidates that the
candidates will receive the necessary regulatory approvals or that they will prove to be
commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties
materialize, actual results may differ materially from those set forth in the forward-looking
statements.
Risks and uncertainties include but are not limited to, general industry conditions and
competition; general economic factors, including interest rate and currency exchange rate
fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the
United States and internationally; global trends toward health care cost containment;
technological advances, new products and patents attained by competitors; challenges inherent
in new product development, including obtaining regulatory approval; the company’s ability to
accurately predict future market conditions; manufacturing difficulties or delays; financial
instability of international economies and sovereign risk; dependence on the effectiveness of the
company’s patents and other protections for innovative products; and the exposure to litigation,
including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement,
whether as a result of new information, future events or otherwise. Additional factors that could
cause results to differ materially from those described in the forward-looking statements can be
found in the company’s Annual Report on Form 10-K for the year ended December 31, 2023
and the company’s other filings with the Securities and Exchange Commission (SEC) available
at the SEC’s Internet site (www.sec.gov).
Appendix
Generic product names are provided below.
Pharmaceutical
BRIDION (sugammadex)
GARDASIL (Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine,
Recombinant)
GARDASIL 9 (Human Papillomavirus 9-valent Vaccine, Recombinant)
JANUMET (sitagliptin and metformin HCl)
JANUVIA (sitagliptin)
KEYTRUDA (pembrolizumab)
LAGEVRIO (molnupiravir)
Lenvima (lenvatinib)
Lynparza (olaparib)
M-M-R II (Measles, Mumps and Rubella Virus Vaccine Live)
PROQUAD (Measles, Mumps, Rubella and Varicella Virus Vaccine Live)
ROTATEQ (Rotavirus Vaccine, Live, Oral, Pentavalent)
VARIVAX (Varicella Virus Vaccine Live)
VAXNEUVANCE (Pneumococcal 15-valent Conjugate Vaccine)
WINREVAIR (sotatercept-csrk)

-- 11 of 12 --

- 12 -
Animal Health
BRAVECTO (fluralaner)
###
Media Contacts: 	Investor Contacts:
Robert Josephson
(203) 914-2372
robert.josephson@merck.com
Michael Levey
(215) 872-1462
michael.levey@merck.com
Peter Dannenbaum
(732) 594-1579
peter.dannenbaum@merck.com
Steven Graziano
(732) 594-1583
steven.graziano@merck.com

-- 12 of 12 --